secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001193125-24-067432
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma FY2023: JELMYTO revenue $82.7M (+28% YoY), net loss narrows, UGN-102 NDA on track
--------------------------------------------------------------------------------

- Full year JELMYTO net revenue $82.7M, up ~28% YoY from $64.4M; Q4 revenue $23.5M (+30% YoY).
- Net loss narrowed to $102.2M ($3.55/share) for FY2023 from $109.8M ($4.81/share) in 2022.
- Rolling NDA for UGN-102 initiated Jan 2024; completion target Sep 2024, potential FDA decision Q1 2025.
- Licensed next-gen mitomycin formulations (UGN-103/104) from medac with IP protection until Dec 2041.
- Restructured Pharmakon loan: lower interest rate, deferred payback, up to $100M additional credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/0001193125-24-067432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/d675566d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-067432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer